Issues & Trends

JK Synapse Reports Cumulative Third-Quarter Revenue of 62 Billion Won… Up 55% Year-Over-Year

SG&A Expenses Reduced by Approximately 70% in the Third Quarter

Kwon Oh Seok
2026-11-17 09:54:39
[Edaily Reporter Kwon Oh Seok ] Sonid(060230)has further enhanced its financial stability by simultaneously raising capital and repaying debt. Coupled with cost-efficiency measures—including significant reductions in fixed expenses such as selling, general, and administrative expenses—the company is showing signs of improvement not only in revenue growth but also in its profit structure.
(Photo: JK Synapse)

JK Synapse announced its consolidated financial results for the third quarter of 2026 via a regulatory filing on the 16th. The most notable development is the improvement in financial soundness indicators. As of the end of the third quarter of this year, the debt-to-equity ratio stood at 99.7%, down 36.5 percentage points (p) from the end of last year (136.2%), bringing it below the 100% threshold.
This improvement in the debt-to-equity ratio resulted from simultaneous capital expansion and debt reduction. Through the payment of funds from a rights offering and the conversion of convertible bonds (CBs) into shares, the company increased its total capital by approximately 10.71 billion won—from about 64.09 billion won at the end of last year to about 74.80 billion won at the end of the third quarter of this year.
At the same time, the company reduced its short-term borrowings and outstanding corporate bond balances, thereby mitigating short-term liquidity risks. As the scale of borrowing decreased, financial expenses in the third quarter of this year also fell by approximately 22% compared to the same period last year, which had a positive impact on safeguarding non-operating income.
Significant changes were also observed in business scale and profit and loss indicators. Cumulative consolidated revenue for January through September of this year totaled approximately 61.98 billion won, representing growth of about 55% compared to the same period last year (approximately 39.94 billion won).
On a standalone basis, third-quarter revenue was 14.69 billion won, down 26.5% from the same period last year (19.98 billion won); however, the company prevented a deterioration in profitability through rigorous cost control. The company reduced selling, general, and administrative expenses (SG&A) in the third quarter by approximately 70%, from about 11.18 billion won in the same period last year to about 3.36 billion won. As a result, the company posted an operating loss of approximately 1.63 billion won in the third quarter, narrowing the deficit by about 30% compared to the same period last year (approximately 2.33 billion won).
A JK Synapse official stated, “We have strengthened our financial foundation by lowering the debt-to-equity ratio below 100% through capital expansion and debt repayment, alongside growth in cumulative revenue,” adding, “Based on our stabilized financial structure and cost efficiency, we will enhance the competitiveness of our core businesses and continue profitability-focused management, focusing on restoring earnings and enhancing shareholder value.”

Economy

Corporation

IT·Science

Economy

[37th SRE][Survey] “Lego Land Nightmare Repeats”: Han Shin Rating Plummets to Last Place… Han Ki Rating Achieves First Place for Fifth Consecutive Year

Korea Ratings (KRI) took the top spot in the “Credit Rating Reliability” category of the 37th Edaily Survey of Credit Rating Experts (SRE), maintaining its number one position for the fifth consecutiv…
2026-11-17 10:00:08

Corporation

ViGenCell Inc.’s ‘VT-EBV-N’ Designated for Expedited Review by the Ministry of Food and Drug Safety… Seeking Conditional Approval

ViGenCell Inc.(308080)is expected to accelerate its efforts to secure domestic approval for “VT-EBV-N,” a treatment for NK/T-cell lymphoma currently under development. With the drug designated as an a…
2026-11-17 10:23:03

IT·Science

Celltrion’s ‘Herzuma’ Wins Brazilian Government Tender for 7 Consecutive Years… Follow-up Products Also Set to Launch

“Herjumma,” a treatment for breast and stomach cancer. (Active ingredient: trastuzumab) (Photo: Celltrion) Celltrion(068270)has secured a large-scale supply contract for “Herjumma” (active ingredi…
2026-11-17 10:29:04